$AGIO on NASDAQ
March 05, 2024
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
February 22, 2024
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
February 15, 2024
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 02, 2024
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
January 08, 2024
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
January 03, 2024
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
January 02, 2024
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
December 09, 2023
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
November 20, 2023
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
November 02, 2023
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
November 02, 2023
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
October 19, 2023
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
August 29, 2023
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
August 03, 2023
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
August 03, 2023
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
July 13, 2023
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
June 26, 2023
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
June 05, 2023
Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023
May 25, 2023
Agios Appoints Catherine Owen to Board of Directors
May 11, 2023
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
May 04, 2023
Agios Reports Business Highlights and First Quarter 2023 Financial Results
April 25, 2023
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
April 19, 2023
Agios Appoints Jeffrey Capello to Board of Directors
April 13, 2023
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
April 12, 2023
Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero
April 03, 2023
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
March 02, 2023
Agios to Participate in March Investor Conferences
February 28, 2023
Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
February 23, 2023
Agios Reports Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
January 08, 2023
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
January 03, 2023
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
December 21, 2022
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
December 11, 2022
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
December 10, 2022
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition
December 06, 2022
Agios Appoints Tsveta Milanova as Chief Commercial Officer
November 30, 2022
Agios to Participate in December Investor Conference
November 10, 2022
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
November 03, 2022
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
November 03, 2022
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
October 27, 2022
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
October 20, 2022
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
September 26, 2022
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
September 19, 2022
Agios Appoints Cecilia Jones as Chief Financial Officer
September 16, 2022
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
August 24, 2022
Agios to Participate in September Investor Conferences
August 18, 2022
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
August 15, 2022
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
August 11, 2022
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
August 08, 2022
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
- No Recent Filings Found.
